Editorial: Basic, clinical, and translational studies of Yao syndrome and other NOD2 related diseases

John M. Davis,Christine McDonald,Qingping Yao

DOI: https://doi.org/10.3389/fimmu.2024.1521815

IF: 7.3

2024-11-18

Frontiers in Immunology

Abstract:Nucleotide-binding oligomerization domain containing protein 2 (NOD2) is a member of NOD-like receptor family (NLRs) (1). The NLR family was first discovered in the early 2000s through the complementary efforts of several research teams, which resulted in multiple names for the same molecule (2)(3)(4)(5)(6). The family nomenclature has since been standardized; however earlier literature may refer to NOD2 as caspase recruitment domain-containing protein 15 (CARD15) based on its molecular structure that includes two N-terminal CARDs. NOD2 is an intracellular microbe sensor that plays important roles in infection defense, control of inflammation, and apoptosis (7). The discovery that NOD2 missense and frameshift mutations are risk factors for the inflammatory bowel disease Crohn's disease demonstrates the importance of this molecule in inflammatory disease (8,9). Additional genetic variants of NOD2 are linked to other autoinflammatory diseases, such as Blau syndrome and Yao syndrome (10); however, much more needs to be done to define clinical phenotypes of NOD2-associated diseases and understand the molecular mechanisms underlying disease pathogenesis. The research topic "Basic, clinical, and translational studies of Yao syndrome and other NOD2 related diseases" brings together several articles to provide further insights into this area and proposes a new concept for defining autoinflammatory diseases.In 2002, several highly penetrant variants on exon 4 of NOD2 were found to cause Blau syndrome (BS, OMIM#186580), a pediatric (early onset) autosomal dominant granulomatous disease characterized by granulomatous arthritis, uveitis, and dermatitis (11). Initially, these NOD2 variants were thought to result in overactive NOD2-dependent pro-inflammatory signaling (12); however, more recent studies indicate that the loss of NOD2 cross-regulatory function controlling the activity of other inflammatory pathways (13) may be a greater contributor to the pathobiology of BS. In this collection, two articles investigate strategies targeting these altered NOD2 activities in novel treatment approaches for BS. Multiple immune suppressive therapies have been empirically applied as BS treatments (14). The molecular biology study from Dr.Kambe's group (Ueki Y, et al). in Japan reveals that the Janus kinase inhibitor tofacitinib suppresses pro-inflammatory cytokine production through suppression of NOD2 expression. The case report from Dr. McBride's group in the US (Jensen ME, et al) demonstrates successful treatment of BS with a combination of methotrexate and hydroxychloroquine; two agents thought to interfere with expression and activation of NOD2 and other related immune sensor proteins (15,16). Although more research is needed, these findings suggest that evaluation and targeting of NOD2 expression levels may be beneficial in shaping an optimal treatment strategy for BS patients.A more recently described NOD2-associated autoinflammatory disease is Yao syndrome (YAOS, OMIM#617321) (17). YAOS is a systemic inflammatory disease characterized by recurrent fever, dermatitis, arthralgias, distal leg swelling, gastrointestinal, sicca-like symptoms and eyelid swelling to form a complete or partial clinical constellation (18) (19). This disease is linked to multiple NOD2 variants, such as IVS8+158, IVS8+158/R702W, IVS8+158/L1007fs, IVS8+158/V955I (20). Originally described as a disease that predominantly affected adult Caucasian women, five articles in this research collection expand our understanding of the presentation of YAOS in other age and ethnic groups, as well as refine the associated clinical phenotypes. The large study of 167 Greek patients with autoinflammatory disease by Dr. Laskari and colleagues (Karamanakos A, et al) reveals that 7% (12/167) or approximately half of the patients with NOD2 variants were diagnosed with YAOS and included both pediatric and adult patients. Dr. Shen and colleagues (Zhang J, et al) report on the identification of YAOS in a Chinese population and key differences in disease presentation that include a more balanced sex ratio and a higher proportion of recurrent fever and proteinuria/hematuria than found in Caucasian cohorts. Additionally, similar to genetic analyses of Crohn's disease in different ethnic groups (20), the NOD2 variants associated with Chinese YAOS patients were distinct from Caucasian populations. Further substantiating clinical and genotyping features of YAOS, Dr. Davis and colleagues reports 22 adult patients of European ancestry (Williamson KA, et al) and Dr. Yao's team provide a comprehensive study of the clinical phenotype, genotype and therapeutic response of 152 adult YAOS patients (Nomani H, et al). While there is no epidemiologic study of YAOS, the studies in this collection indicate that YAOS is more common than initially thought and impacts a broader spectrum of ethnic backgrounds. We estimate that the prevalence of t -Abstract Truncated-

immunology